" class="no-js "lang="en-US"> Roche Showcases Commitment to Innovative Diagnostic Solutions
Wednesday, June 19, 2024

Roche Showcases Commitment to Advancing Innovative Diagnostic Solutions

Roche announced today that it will be showcasing innovative laboratory solutions and digital diagnostics through – “Innovation Past, Present and Future” at this year’s WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May. Attendees will have the opportunity to experience first-hand Roche’s latest technological advancements in lab automation, serum work area, molecular and point-of-care solutions and find out more about how the company is transforming patient care through advancements in breakthrough high-medical value diagnostic and digital solutions.

“With the ever-changing needs of the healthcare system, laboratories and clinicians are expected to optimise laboratory operations and efficiencies while improving patient care,” said Ann Costello, Head of Roche Diagnostics Solutions at Roche Diagnostics. “We are pleased to present the next generation of innovative solutions that simplify and streamline testing for laboratories of all sizes, throughputs and disciplines, while supporting clinical decision-making to improve patient care.”

“Laboratories have a unique opportunity to connect siloed data across systems and points of care for greater insights,” said Moritz Hartmann, Head of Roche Information Solutions at Roche Diagnostics. “At Roche, we are working closely together with lab leaders to enable more patient-centred care. Our navify® portfolio of integrated digital solutions enables open digital ecosystems that connect to innovations, drive operational efficiencies and generate actionable insights for improved patient care.”

Roche will be featuring new innovations, such as several molecular systems from the growing PCR portfolio – the cobas® 5800 and the new LightCycler® PRO System, launching later this year. A prototype for the new cobas® Mass Spec system will be revealed, bringing mass spectrometry into the routine testing environment. The system will complement the serum work area portfolio so that in the future, healthcare communities will benefit from an extended diagnostic platform offering clinical chemistry, heterogeneous immunoassays, and mass spectrometry. The new cobas® connection modules (CCM Vertical), a flexible modular system that uses lab space effectively, and seamlessly integrates into the existing cobas® connection modules, improving lab efficiency, will also be featured*.

Roche will also introduce its navify digital solutions to the laboratory community. navify digital solutions aim to solve laboratories’ need for seamless and secure connectivity between systems, instruments and even devices from different providers as well as empowering lab leaders to drive operational efficiencies, and help clinicians gain greater medical insights.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more